surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 once weekly for the treatment of obesity in people with (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial 🔴Tirzepatide for obesity and diabetes

Working with a medical provider allows these factors to be evaluated carefully and safely

If you inject tirzepatide in the stomach , the initial onset of side effects may begin slightly sooner, within 1 to 2 hours rather than 2 to 3 hours

Similarly, semaglutide was administered via sub-cutaneous weekly injections with no restrictions on day or time of day (again, consistency of day and time were advised)

Mounjaro also reduced BMI a measure that accounts for growth over time when assessing weight change in children and adolescents by an average of 8.9% for pooled doses, compared with 0.6% for placebo.vi

If pregnancy isnt the goal, effective birth control is a must